NDFOS Co. Ltd (238090) - Total Liabilities
Based on the latest financial reports, NDFOS Co. Ltd (238090) has total liabilities worth ₩14.82 Billion KRW (≈ $10.04 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 238090 shareholders equity momentum to track the company's year-over-year net asset growth rate.
NDFOS Co. Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how NDFOS Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See NDFOS Co. Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
NDFOS Co. Ltd Competitors by Total Liabilities
The table below lists competitors of NDFOS Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
A2Z Infra Engineering Limited
NSE:A2ZINFRA
|
India | Rs4.58 Billion |
|
Catena Media plc
ST:CTM
|
Sweden | Skr44.48 Million |
|
Shanghai Kai Kai Industry Co Ltd B
SHG:900943
|
China | $878.36 Million |
|
Avertronics
TWO:3597
|
Taiwan | NT$1.01 Billion |
|
Shanghai Material Trading Co Ltd B
SHG:900927
|
China | $463.81 Million |
|
TRC Synergy Bhd
KLSE:5054
|
Malaysia | RM298.89 Million |
|
Innovative Solutions Ecosystem SA
MC:ISE
|
Spain | €7.39 Million |
|
Golden Lime PCL
BK:SUTHA
|
Thailand | ฿1.26 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down NDFOS Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NDFOS Co. Ltd (238090) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NDFOS Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NDFOS Co. Ltd (2014–2024)
The table below shows the annual total liabilities of NDFOS Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩15.70 Billion ≈ $10.64 Million |
-5.75% |
| 2023-12-31 | ₩16.66 Billion ≈ $11.29 Million |
-51.77% |
| 2022-12-31 | ₩34.55 Billion ≈ $23.41 Million |
-50.44% |
| 2021-12-31 | ₩69.71 Billion ≈ $47.24 Million |
+67.85% |
| 2020-12-31 | ₩41.53 Billion ≈ $28.15 Million |
-47.23% |
| 2019-12-31 | ₩78.70 Billion ≈ $53.34 Million |
+71.88% |
| 2018-12-31 | ₩45.79 Billion ≈ $31.03 Million |
+275.02% |
| 2017-12-31 | ₩12.21 Billion ≈ $8.27 Million |
+47.33% |
| 2016-12-31 | ₩8.29 Billion ≈ $5.62 Million |
-20.84% |
| 2015-12-31 | ₩10.47 Billion ≈ $7.09 Million |
-23.81% |
| 2014-12-31 | ₩13.74 Billion ≈ $9.31 Million |
-- |
About NDFOS Co. Ltd
NDFOS Co., Ltd. operates as a tape and film company in South Korea. The company offers adhesive tapes, such as waterproof tapes, light-shielding tapes, heat reaction tapes, battery fixing tapes, thin film tapes, convergence type functional tapes, and heat radiation tapes; functional films, including automobiles, industries, and everyday life. It also develops ARS and STR, anticancer drugs for can… Read more